FDA Panel Considers Relaxing Peptide Restrictions
An FDA advisory panel is evaluating whether to ease current restrictions on certain peptides, potentially expanding access for research and therapeutic use. The decision could impact the development of new treatments and the regulatory landscape for these compounds.